Glycoregulation is not altered by short-term administration of diltiazem in nondiabetic humans.
In this study changes in glucose assimilation during an intravenous glucose tolerance test (IVGTT) was investigated in 12 clinically healthy normotensive women with a body mass index (BMI) of 25 kg/m2 (range 22-31). This was assessed by coefficient Kg, the level of glycosylated proteins and insulin, C-peptide and contraregulating hormone secretion after seven days of oral administration of diltiazem, a calcium current blocker (180 mg per day). In spite of the fact that diltiazem protracted electrocardiographic QT interval from 0.16 +/- 0.008 to 0.18 +/- 0.009 s. (p < 0.01), QaT from 0.29 +/- 0.007 to 0.31 +/- 0.008 s. (p < 0.05), QeT from 0.35 +/- 0.009 to 0.37 +/- 0.009 s. (p < 0.01), it did not affect Kg in any significant way, nor did it affect the glycosylated protein levels, insulin and C-peptide secretion, nor the secretion of adrenaline, noradrenaline, dopamine, cortisol and growth hormone. Thus although diltiazem is a highly effective drug as far as the cardiovascular system is concerned, short-term administration of therapeutic doses of 180 mg/day is not associated with glycoregulatory risks.
Zofková
I
I
Institute of Endocrinology Prague/Czech Republic.
Stolba
P
P
Husek
P
P
D000328:Adult; D015992:Body Mass Index; D002096:C-Peptide / Q000097:blood / Q000652:urine; D004110:Diltiazem / Q000008:administration & dosage / Q000494:pharmacology*; D004562:Electrocardiography; D005260:Female; D005947:Glucose / Q000378:metabolism*; D005951:Glucose Tolerance Test; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood
D002096:C-Peptide; D006023:Glycoproteins; D007328:Insulin; D004110:Diltiazem; D005947:Glucose